Study of adebrelimab plus apatinib after liver cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your liver cancer within the last 4 to 12 weeks.
- You have a high risk of the cancer coming back after surgery (e.g., large or multiple tumors, or spread to blood vessels).
- You have not had any prior medications or infusions for liver cancer (except surgery).
- Your liver is working fairly well (Child-Pugh score A or B, less than 7 points).
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medicines (adebrelimab and apatinib) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combo can slow down the cancer and improve outcomes.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of three drugs given before and after surgery for liver cancer that can be removed. The goal is to see if this approach can help reduce the chance of the cancer coming back.
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
This trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy helps shrink stomach cancer before surgery. It aims to improve outcomes for people with advanced stomach cancer that cannot be removed or has spread.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Carcinoma, Hepatocellular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.